NO20022835L - Substituerte imidazol neuropeptid Y Y5 reseptorantagonister - Google Patents

Substituerte imidazol neuropeptid Y Y5 reseptorantagonister

Info

Publication number: NO20022835L
Authority: NO; Norway
Prior art keywords: neuropeptide; receptor antagonists; substituted imidazole; imidazole; substituted
Prior art date: 1999-12-16

Application number

NO20022835A

Other languages

English (en)

Norwegian (no)

Other versions

NO20022835D0 (no

Inventor

Andrew W Stamford

Craig D Boyle

Ying Huang

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-16

Filing date

2002-06-14

Publication date

2002-08-16

2002-06-14 Application filed by Schering Corp filed Critical Schering Corp

2002-06-14 Publication of NO20022835D0 publication Critical patent/NO20022835D0/no

2002-08-16 Publication of NO20022835L publication Critical patent/NO20022835L/no

Links

RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 2
101710151321 Melanostatin Proteins 0.000 title 1
102400000064 Neuropeptide Y Human genes 0.000 title 1
102100029549 Neuropeptide Y receptor type 5 Human genes 0.000 title 1
101710198055 Neuropeptide Y receptor type 5 Proteins 0.000 title 1
150000002460 imidazoles Chemical class 0.000 title 1
URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 title 1
239000002464 receptor antagonist Substances 0.000 title 1
229940044551 receptor antagonist Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Diabetes (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20022835A 1999-12-16 2002-06-14 Substituerte imidazol neuropeptid Y Y5 reseptorantagonister NO20022835L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US17122399P	1999-12-16	1999-12-16
PCT/US2000/033832 WO2001044201A1 (en)	1999-12-16	2000-12-14	Substituted imidazole neuropeptide y y5 receptor antagonists

Publications (2)

Publication Number	Publication Date
NO20022835D0 NO20022835D0 (no)	2002-06-14
NO20022835L true NO20022835L (no)	2002-08-16

Family

ID=22622991

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20022835A NO20022835L (no)	1999-12-16	2002-06-14	Substituerte imidazol neuropeptid Y Y5 reseptorantagonister

Country Status (26)

Country	Link
US (2)	US6444687B1 (pl)
EP (1)	EP1237875B1 (pl)
JP (2)	JP4180276B2 (pl)
KR (1)	KR20020062342A (pl)
CN (1)	CN1227236C (pl)
AR (1)	AR032292A1 (pl)
AT (1)	ATE303364T1 (pl)
AU (1)	AU2261401A (pl)
BR (1)	BR0017025A (pl)
CA (1)	CA2393821C (pl)
CZ (1)	CZ20022100A3 (pl)
DE (1)	DE60022386T2 (pl)
ES (1)	ES2243337T3 (pl)
HK (1)	HK1045503A1 (pl)
HU (1)	HUP0301218A2 (pl)
IL (1)	IL149872A0 (pl)
MX (1)	MXPA02006016A (pl)
MY (1)	MY138524A (pl)
NO (1)	NO20022835L (pl)
NZ (1)	NZ519272A (pl)
PL (1)	PL356485A1 (pl)
RU (1)	RU2002119019A (pl)
SK (1)	SK8452002A3 (pl)
TR (1)	TR200201568T2 (pl)
WO (1)	WO2001044201A1 (pl)
ZA (1)	ZA200204350B (pl)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002543067A (ja)	1999-04-22	2002-12-17	シナプティック・ファーマスーティカル・コーポレーション	選択的なｎｐｙ（ｙ５）のアンタゴニスト
US6989379B1 (en)	1999-04-22	2006-01-24	H. Lundbick A/S	Selective NPY (Y5) antagonists
US6340683B1 (en)	1999-04-22	2002-01-22	Synaptic Pharmaceutical Corporation	Selective NPY (Y5) antagonists (triazines)
US7273880B2 (en)	1999-06-30	2007-09-25	H. Lunbeck A/S	Selective NPY (Y5) antagonists
AU773892B2 (en) *	1999-06-30	2004-06-10	H. Lundbeck A/S	Selective NPY (Y5) antagonists
DE10035908A1 (de)	2000-07-21	2002-03-07	Asta Medica Ag	Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel
FR2818978B1 (fr) *	2000-12-28	2003-02-28	Sod Conseils Rech Applic	Modulateurs de canaux sodiques derives de 2-piperidylimidazoles
FR2825926A1 (fr)	2001-06-14	2002-12-20	Sod Conseils Rech Applic	Derives d'imidazoles modulant les canaux sodiques
EP1405636A4 (en) *	2001-06-26	2009-04-15	Takeda Pharmaceutical	FUNCTIONAL REGULATOR FOR RETINOID RELATIVE RECEPTOR
US7297708B2 (en) *	2001-09-06	2007-11-20	Bristol-Myers Squibb Company	Heteroaromatic substituted cyclopropane as corticotropin releasing hormone ligands
CA2403307A1 (en) *	2001-10-23	2003-04-23	Neurogen Corporation	Substituted 2-cyclohexyl-4-phenyl-1h-imidazole derivatives
PL372390A1 (pl) *	2002-02-05	2005-07-25	Novo Nordisk A/S	Nowe arylo-i heteroarylopiperazyny
RU2361869C2 (ru) *	2002-02-05	2009-07-20	ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи	Новые арил- и гетероарилпиперазины
US7105526B2 (en)	2002-06-28	2006-09-12	Banyu Pharmaceuticals Co., Ltd.	Benzimidazole derivatives
FR2846655B1 (fr) *	2002-11-05	2004-12-24	Servier Lab	Nouveaux derives de la pyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7332508B2 (en) *	2002-12-18	2008-02-19	Novo Nordisk A/S	Substituted homopiperidine, piperidine or pyrrolidine derivatives
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
AU2004210711B2 (en) *	2003-02-12	2010-07-08	Transtech Pharma, Inc.	Substituted azole derivatives as therapeutic agents
FR2855520B1 (fr) *	2003-05-27	2007-06-29	Sod Conseils Rech Applic	Nouveaux derives d'imidazoles, leur preparation et leur utilisation en tant que medicament
ES2311847T3 (es) *	2003-05-27	2009-02-16	Societe De Conseils De Recherches Et D'applications Scientifiques ( S.C.R.A.S.)	Nuevos derivados de imidazoles, su prepracion y su utilizacion como medicamento.
WO2005028438A1 (ja)	2003-09-22	2005-03-31	Banyu Pharmaceutical Co., Ltd.	新規ピペリジン誘導体
US20080125403A1 (en)	2004-04-02	2008-05-29	Merck & Co., Inc.	Method of Treating Men with Metabolic and Anthropometric Disorders
WO2006004142A1 (ja) *	2004-06-30	2006-01-12	Banyu Pharmaceutical Co., Ltd.	ビアリール誘導体
JP2008515992A (ja)	2004-10-13	2008-05-15	ピーティーシーセラピューティクス，インコーポレーテッド	体細胞変異に起因する疾患の阻止／治療用医薬を製造するための規定化合物の使用
AU2005295752A1 (en) *	2004-10-15	2006-04-27	Amgen Inc.	Imidazole derivatives as vanilloid receptor ligands
DK1814590T4 (da)	2004-11-01	2014-02-24	Amylin Pharmaceuticals Llc	Behandling af obesitet og beslægtede sygdomme.
TW200633990A (en)	2004-11-18	2006-10-01	Takeda Pharmaceuticals Co	Amide compound
EP1877076A4 (en) *	2005-04-15	2012-02-01	Regenertech Pty Ltd	USE OF NEUROPEPTIDES Y (NPY) AND AGONIST OF ANTAGONISTS THEREOF FOR REGENERATING TISSUES
US7737155B2 (en)	2005-05-17	2010-06-15	Schering Corporation	Nitrogen-containing heterocyclic compounds and methods of use thereof
GB0510141D0 (en) *	2005-05-18	2005-06-22	Addex Pharmaceuticals Sa	Novel compounds B3
EP1892241B1 (en)	2005-05-30	2016-03-30	Msd K.K.	Novel piperidine derivative
RU2444516C2 (ru) *	2005-06-29	2012-03-10	Янссен Фармацевтика Нв	Способ синтеза производных имидазоламинокислот и родственных соединений
CN103110635A (zh)	2005-07-04	2013-05-22	海波因特制药有限责任公司	组胺h3受体拮抗剂
EP1916239A4 (en)	2005-08-10	2009-10-21	Banyu Pharma Co Ltd	PYRIDOLVERBINDUNG
EP2330125A3 (en)	2005-08-11	2012-12-12	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides with selectable properties
EP1922336B1 (en)	2005-08-11	2012-11-21	Amylin Pharmaceuticals, LLC	Hybrid polypeptides with selectable properties
US7875633B2 (en)	2005-08-24	2011-01-25	Banyu Pharmaceutical Co., Ltd.	Phenylpyridone derivative
WO2007029847A1 (ja)	2005-09-07	2007-03-15	Banyu Pharmaceutical Co., Ltd.	二環性芳香族置換ピリドン誘導体
KR20080048502A (ko)	2005-09-29	2008-06-02	머크 앤드 캄파니 인코포레이티드	멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
RU2008119687A (ru)	2005-10-21	2009-11-27	Новартис АГ (CH)	Комбинации органических соединений
AU2006307046A1 (en)	2005-10-27	2007-05-03	Msd K.K.	Novel benzoxathiin derivative
RU2428423C2 (ru)	2005-11-10	2011-09-10	Баниу Фармасьютикал Ко., Лтд.	Азазамещенные спиропроизводные
NZ571869A (en) *	2006-04-06	2011-11-25	Prosidion Ltd	Heterocyclic GPCR agonists
CA2653062A1 (en)	2006-05-23	2007-11-29	Transtech Pharma, Inc.	6- (4-cyclopropylpiperazin-1-yl) -2 ' -methyl- [3, 4 ' ] -bipyridine and its use as a medicament
ATE538116T1 (de)	2006-05-29	2012-01-15	High Point Pharmaceuticals Llc	3-(1,3-benyodioxol-5-yl)-6- (4- cyclopropylpiperazin-1-yl)-pyridazin, dessen salze und solvate und dessen verwendung als histamin-h3-rezeptorantagonist
PE20080948A1 (es)	2006-07-25	2008-09-10	Irm Llc	Derivados de imidazol como moduladores de la senda de hedgehog
AU2007300627B2 (en)	2006-09-22	2012-02-16	Merck Sharp & Dohme Corp.	Method of treatment using fatty acid synthesis inhibitors
EP2072519A4 (en)	2006-09-28	2009-10-21	Banyu Pharma Co Ltd	DIARYLKETIMINDERIVAT
AU2008233662B2 (en)	2007-04-02	2012-08-23	Msd K.K.	Indoledione derivative
US8372859B2 (en)	2007-04-11	2013-02-12	Merck, Sharp & Dohme Corp.	CGRP receptor antagonists with tertiary amide, sulfonamide, carbamate and urea end groups
WO2008151257A2 (en)	2007-06-04	2008-12-11	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
JP5443342B2 (ja) *	2007-06-08	2014-03-19	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	ピペリジン／ピペラジン誘導体
EP2014656A3 (en)	2007-06-11	2011-08-24	High Point Pharmaceuticals, LLC	New heteocyclic h3 antagonists
AU2009220605A1 (en)	2008-03-06	2009-09-11	Msd K.K.	Alkylaminopyridine derivative
CA2717384A1 (en)	2008-03-28	2009-10-01	Banyu Pharmaceutical Co., Ltd.	Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
CL2009000904A1 (es)	2008-04-21	2010-04-30	Shionogi & Co	Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende.
ES2627848T3 (es)	2008-06-04	2017-07-31	Synergy Pharmaceuticals Inc.	Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009261248A1 (en)	2008-06-19	2009-12-23	Banyu Pharmaceutical Co., Ltd.	Spirodiamine-diarylketoxime derivative
ES2624828T3 (es)	2008-07-16	2017-07-17	Synergy Pharmaceuticals Inc.	Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US20110124674A1 (en)	2008-07-30	2011-05-26	Hiroyuki Kishino	5/5-or 5/6-membered condensed ring cycloalkylamine derivative
US8410284B2 (en)	2008-10-22	2013-04-02	Merck Sharp & Dohme Corp	Cyclic benzimidazole derivatives useful as anti-diabetic agents
MX2011004551A (es)	2008-10-30	2011-05-25	Merck Sharp & Dohme	Antagonistas del receptor de orexina de isonicotinamida.
WO2010051206A1 (en)	2008-10-31	2010-05-06	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US20110245209A1 (en)	2008-12-16	2011-10-06	Schering Corporation	Pyridopyrimidine derivatives and methods of use thereof
US20110243940A1 (en)	2008-12-16	2011-10-06	Schering Corporation	Bicyclic pyranone derivatives and methods of use thereof
JP5642661B2 (ja) *	2009-03-05	2014-12-17	塩野義製薬株式会社	Ｎｐｙｙ５受容体拮抗作用を有するピペリジンおよびピロリジン誘導体
ES2459468T3 (es)	2009-05-15	2014-05-09	Novartis Ag	Arilpiridinas como inhibidores de aldosterona sintasa
JP2013520502A (ja)	2010-02-25	2013-06-06	メルク・シャープ・エンド・ドーム・コーポレイション	有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
CA2826649C (en)	2011-02-25	2016-07-26	Merck Sharp & Dohme Corp.	Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
AR088352A1 (es)	2011-10-19	2014-05-28	Merck Sharp & Dohme	Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
US20140045746A1 (en)	2012-08-02	2014-02-13	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
JP2016516004A (ja)	2013-02-22	2016-06-02	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	抗糖尿病二環式化合物
WO2014139388A1 (en)	2013-03-14	2014-09-18	Merck Sharp & Dohme Corp.	Novel indole derivatives useful as anti-diabetic agents
US9708367B2 (en)	2013-03-15	2017-07-18	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase and their uses
EP2968439A2 (en)	2013-03-15	2016-01-20	Synergy Pharmaceuticals Inc.	Compositions useful for the treatment of gastrointestinal disorders
PL3004138T3 (pl)	2013-06-05	2024-07-29	Bausch Health Ireland Limited	Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie
US20160145242A1 (en) *	2013-07-04	2016-05-26	Nippon Soda Co., Ltd.	Phenylimidazole derivative, and therapeutic medicine or preventive medicine for inflammatory disease, etc.
CR20160136A (es)	2013-08-28	2016-08-04	Medivation Technologies Inc	Compuestos heterocíclicos
WO2015051496A1 (en)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
BR112017003745A2 (pt)	2014-08-29	2017-12-05	Tes Pharma S R L	inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
EP3265457A1 (en)	2015-03-04	2018-01-10	Medivation Technologies LLC	Sterol regulatory element-binding proteins (srebps) inhibitors
EP3265088A1 (en)	2015-03-04	2018-01-10	Medivation Technologies LLC	Srebp blockers for use in treating liver fibrosis, elevated cholesterol and insulin resistance
AU2017342083A1 (en)	2016-10-14	2019-04-11	Tes Pharma S.R.L.	Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
WO2018106518A1 (en)	2016-12-06	2018-06-14	Merck Sharp & Dohme Corp.	Antidiabetic heterocyclic compounds
WO2018118670A1 (en)	2016-12-20	2018-06-28	Merck Sharp & Dohme Corp.	Antidiabetic spirochroman compounds
WO2018140504A1 (en) *	2017-01-24	2018-08-02	Patel Manoj K	Compositions and methods for blocking sodium channels
EP3883930A1 (en)	2018-11-20	2021-09-29	Tes Pharma S.r.l.	Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
US11098029B2 (en)	2019-02-13	2021-08-24	Merck Sharp & Dohme Corp.	5-alkyl pyrrolidine orexin receptor agonists
WO2020167701A1 (en)	2019-02-13	2020-08-20	Merck Sharp & Dohme Corp.	Pyrrolidine orexin receptor agonists
EP4010314B1 (en)	2019-08-08	2024-02-28	Merck Sharp & Dohme LLC	Heteroaryl pyrrolidine and piperidine orexin receptor agonists
US20230365533A1 (en)	2020-08-18	2023-11-16	Merck Sharp & Dohme Llc	Bicycloheptane pyrrolidine orexin receptor agonists
JP2024501625A (ja) *	2020-12-11	2024-01-15	ザスクリプスリサーチインスティテュート	神経変性、変性及び代謝性障害の処置のための化合物並びにその使用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3657441A (en)	1970-07-30	1972-04-18	Merck & Co Inc	Method of inhibiting the formation of phenylethanolamine n-methyl transferase with imidazoles
US4642311A (en)	1975-03-03	1987-02-10	Merck & Co., Inc.	β-adrenergic blocking imidazolylphenoxy propanolamines
IT1168008B (it)	1981-07-31	1987-05-20	Zambon Spa	Imidazol-eteri ed ester, procedimenti per prepararli e composizioni farmaceutiche che li contengono
IT1206498B (it)	1983-07-18	1989-04-27	Angeli Inst Spa	Derivati amidinici del4-fenilmidazolo 2-sostituto processi per la loro preparazione e loro uso farmaceutico.
IL83467A0 (en)	1986-08-15	1988-01-31	Fujisawa Pharmaceutical Co	Imidazole derivatives,processes for their preparation and pharmaceutical compositions containing the same
JP2700475B2 (ja)	1988-07-30	1998-01-21	コニカ株式会社	非線形光学材料および非線形光学素子
TW270944B (pl)	1993-05-10	1996-02-21	Shikoku Kakoki Co Ltd
EP0712847A4 (en)	1993-08-11	1997-05-28	Nippon Soda Co	IMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AS A PEST CONTROL
GB9507291D0 (en) *	1995-04-07	1995-05-31	Merck Sharp & Dohme	Therapeutic agents
JP2001508767A (ja)	1996-12-02	2001-07-03	藤沢薬品工業株式会社	５―ｈｔ拮抗作用を有するインドール―ウレア誘導体
US6121260A (en)	1997-07-03	2000-09-19	Neurogen Corporation	Method of treating conditions susceptible to modulation of NPY receptors with diarylimidazole derivatives
FR2772377B1 (fr) *	1997-12-12	2000-01-07	Synthelabo	Derives de 1-(1-h-imidazol-2-yl)pyrrolidines et 1-(1-h-imidazol-2-ylpiperidines), leur preparation et leur application en therapeutique
US6054590A (en) *	1998-03-25	2000-04-25	Bristol-Myers Squibb Company	Imidazolone anorectic agents: II. phenyl derivatives
JP2002543067A (ja)	1999-04-22	2002-12-17	シナプティック・ファーマスーティカル・コーポレーション	選択的なｎｐｙ（ｙ５）のアンタゴニスト
AU2935200A (en)	1999-04-30	2000-11-17	Pfizer Products Inc.	Compounds for the treatment of obesity

2000
- 2000-12-14 DE DE60022386T patent/DE60022386T2/de not_active Expired - Lifetime
- 2000-12-14 JP JP2001544691A patent/JP4180276B2/ja not_active Expired - Fee Related
- 2000-12-14 BR BR0017025-9A patent/BR0017025A/pt not_active Application Discontinuation
- 2000-12-14 CN CNB008189250A patent/CN1227236C/zh not_active Expired - Fee Related
- 2000-12-14 AT AT00986362T patent/ATE303364T1/de not_active IP Right Cessation
- 2000-12-14 EP EP00986362A patent/EP1237875B1/en not_active Expired - Lifetime
- 2000-12-14 PL PL00356485A patent/PL356485A1/pl unknown
- 2000-12-14 KR KR1020027007619A patent/KR20020062342A/ko not_active Ceased
- 2000-12-14 CA CA002393821A patent/CA2393821C/en not_active Expired - Fee Related
- 2000-12-14 IL IL14987200A patent/IL149872A0/xx unknown
- 2000-12-14 MX MXPA02006016A patent/MXPA02006016A/es not_active Application Discontinuation
- 2000-12-14 HU HU0301218A patent/HUP0301218A2/hu unknown
- 2000-12-14 AR ARP000106641A patent/AR032292A1/es unknown
- 2000-12-14 SK SK845-2002A patent/SK8452002A3/sk unknown
- 2000-12-14 AU AU22614/01A patent/AU2261401A/en not_active Abandoned
- 2000-12-14 WO PCT/US2000/033832 patent/WO2001044201A1/en not_active Ceased
- 2000-12-14 HK HK02106766.7A patent/HK1045503A1/zh unknown
- 2000-12-14 CZ CZ20022100A patent/CZ20022100A3/cs unknown
- 2000-12-14 RU RU2002119019/04A patent/RU2002119019A/ru not_active Application Discontinuation
- 2000-12-14 US US09/737,141 patent/US6444687B1/en not_active Expired - Fee Related
- 2000-12-14 TR TR2002/01568T patent/TR200201568T2/xx unknown
- 2000-12-14 ES ES00986362T patent/ES2243337T3/es not_active Expired - Lifetime
- 2000-12-14 NZ NZ519272A patent/NZ519272A/en unknown
- 2000-12-15 MY MYPI20005922A patent/MY138524A/en unknown
2002
- 2002-05-30 ZA ZA200204350A patent/ZA200204350B/en unknown
- 2002-06-14 NO NO20022835A patent/NO20022835L/no not_active Application Discontinuation
- 2002-07-23 US US10/200,966 patent/US6632828B2/en not_active Expired - Fee Related
2006
- 2006-04-12 JP JP2006110338A patent/JP2006199710A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
JP2003517479A (ja)	2003-05-27
JP2006199710A (ja)	2006-08-03
CN1434806A (zh)	2003-08-06
CN1227236C (zh)	2005-11-16
ES2243337T3 (es)	2005-12-01
HK1045503A1 (zh)	2002-11-29
NZ519272A (en)	2004-02-27
CZ20022100A3 (cs)	2002-09-11
US20030114465A1 (en)	2003-06-19
DE60022386D1 (de)	2005-10-06
HUP0301218A2 (hu)	2003-08-28
IL149872A0 (en)	2002-11-10
MY138524A (en)	2009-06-30
ZA200204350B (en)	2003-09-01
DE60022386T2 (de)	2006-06-22
EP1237875A1 (en)	2002-09-11
JP4180276B2 (ja)	2008-11-12
SK8452002A3 (en)	2002-11-06
CA2393821C (en)	2009-05-26
EP1237875B1 (en)	2005-08-31
US6444687B1 (en)	2002-09-03
ATE303364T1 (de)	2005-09-15
KR20020062342A (ko)	2002-07-25
PL356485A1 (pl)	2004-06-28
BR0017025A (pt)	2003-01-07
WO2001044201A1 (en)	2001-06-21
AU2261401A (en)	2001-06-25
US6632828B2 (en)	2003-10-14
AR032292A1 (es)	2003-11-05
MXPA02006016A (es)	2002-12-05
CA2393821A1 (en)	2001-06-21
TR200201568T2 (tr)	2002-10-21
NO20022835D0 (no)	2002-06-14
RU2002119019A (ru)	2004-01-10

Legal Events

Date	Code	Title	Description
2005-09-12	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20022835D0 (no)	2002-06-14	Substituerte imidazolneuropeptid Y Y5-reseptorantagonister
DE69905248T2 (de)	2004-01-29	Neuropeptid y5-rezeptorantagonisten
DE60136562D1 (de)	2008-12-24	Heteroaryl-harnstoff-neuropeptid-y-y5-rezeptor-antagonisten
IL159643A0 (en)	2004-06-01	Substituted urea neuropeptide y y5 receptor antagonists
AU2001294547A1 (en)	2002-03-26	Substituted urea neuropeptide y y5 receptor antagonists
ATE280157T1 (de)	2004-11-15	4-aroyl-piperidin-ccr-3 rezeptor antagonisten iii
DE69919171D1 (de)	2004-09-09	Muskarin-rezeptor antagonisten
NO20015779L (no)	2001-11-27	Bradykinin-reseptorantagonister
NO20004503D0 (no)	2000-09-08	Vitronectin-reseptor-antagonister
NO20016053D0 (no)	2001-12-11	IL-8 reseptor-antagonister
AU1908400A (en)	2000-06-19	Benzimidazole compounds that are vitronectin receptor antagonists
NO20016052D0 (no)	2001-12-11	IL-8-reseptor-antagonister
DK1180028T3 (da)	2007-05-21	IL-8-receptorantagonister
NO20015662D0 (no)	2001-11-20	Oralt aktive A1-adenosinreseptorantagonister
ATE264301T1 (de)	2004-04-15	Muscarin-antagonisten
DZ3333A1 (fr)	2001-10-04	Antagonistes de recepteurs d'il-8
DE60106572D1 (de)	2004-11-25	IMIDAZOLVERBINDUNGEN ALS Alpha2-ADRENOREZEPTOREN ANTAGONISTEN
NO20021113D0 (no)	2002-03-06	Vitronectin-reseptor-antagonister
NO20015774L (no)	2001-11-27	IL-8 reseptorantagonister
IS6818A (is)	2003-05-15	Histamín viðtaka mótlyf
NO20010620D0 (no)	2001-02-06	Vitronektinreseptor-antagonister
NO20016065L (no)	2001-12-12	IL-8-reseptor-antagonister
NO20016102D0 (no)	2001-12-14	IL-8 reseptorantagonister
DK1218005T3 (da)	2005-04-11	Vitronectinreptorantagonister
HK1036065A (en)	2001-12-21	Benzimidazole compounds that are vitronectin receptor antagonists